Last reviewed · How we verify
DBV712
DBV712 is an epicutaneous immunotherapy (EPIT) that delivers allergen to the immune system through the skin to induce immune tolerance.
DBV712 is an epicutaneous immunotherapy (EPIT) that delivers allergen to the immune system through the skin to induce immune tolerance. Used for Peanut allergy (oral immunotherapy tolerance induction).
At a glance
| Generic name | DBV712 |
|---|---|
| Also known as | ViaskinTM Peanut |
| Sponsor | DBV Technologies |
| Drug class | Epicutaneous immunotherapy (EPIT) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
DBV712 uses DBV Technologies' proprietary Viaskin patch technology to apply allergen extract to intact skin, targeting skin-associated lymphoid tissue to promote regulatory T cell responses and immune tolerance. This epicutaneous route of allergen delivery is designed to reprogram the immune system to reduce allergic responses without systemic absorption.
Approved indications
- Peanut allergy (oral immunotherapy tolerance induction)
Common side effects
- Application site reactions (erythema, pruritus)
- Eczema exacerbation
- Allergic reactions
Key clinical trials
- Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) (PHASE3)
- Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age (PHASE3)
- Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
- Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy (PHASE3)
- Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children (PHASE3)
- Viaskin® Peanut (DBV712) Expanded Access Protocol
- Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children (PHASE3)
- A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DBV712 CI brief — competitive landscape report
- DBV712 updates RSS · CI watch RSS
- DBV Technologies portfolio CI